CA2545359C - Compositions and methods for regulation of tumor necrosis factor-alpha - Google Patents

Compositions and methods for regulation of tumor necrosis factor-alpha Download PDF

Info

Publication number
CA2545359C
CA2545359C CA2545359A CA2545359A CA2545359C CA 2545359 C CA2545359 C CA 2545359C CA 2545359 A CA2545359 A CA 2545359A CA 2545359 A CA2545359 A CA 2545359A CA 2545359 C CA2545359 C CA 2545359C
Authority
CA
Canada
Prior art keywords
protein
cells
leu
glu
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2545359A
Other languages
English (en)
French (fr)
Other versions
CA2545359A1 (en
Inventor
Soo-Hyun Kim
Charles A. Dinarello
Tania Azam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Colorado Springs
Original Assignee
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Colorado Springs filed Critical University of Colorado Colorado Springs
Publication of CA2545359A1 publication Critical patent/CA2545359A1/en
Application granted granted Critical
Publication of CA2545359C publication Critical patent/CA2545359C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
CA2545359A 2003-11-12 2004-11-12 Compositions and methods for regulation of tumor necrosis factor-alpha Expired - Fee Related CA2545359C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51981803P 2003-11-12 2003-11-12
US60/519,818 2003-11-12
PCT/US2004/037578 WO2005047478A2 (en) 2003-11-12 2004-11-12 Compositions and methods for regulation of tumor necrosis factor-alpha

Publications (2)

Publication Number Publication Date
CA2545359A1 CA2545359A1 (en) 2005-05-26
CA2545359C true CA2545359C (en) 2012-11-06

Family

ID=34590450

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2545359A Expired - Fee Related CA2545359C (en) 2003-11-12 2004-11-12 Compositions and methods for regulation of tumor necrosis factor-alpha

Country Status (12)

Country Link
US (4) US7560265B2 (cg-RX-API-DMAC10.html)
EP (2) EP2357238A3 (cg-RX-API-DMAC10.html)
JP (2) JP4979385B2 (cg-RX-API-DMAC10.html)
CN (1) CN101018808B (cg-RX-API-DMAC10.html)
AU (1) AU2004290049B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0416467A (cg-RX-API-DMAC10.html)
CA (1) CA2545359C (cg-RX-API-DMAC10.html)
EA (1) EA012567B1 (cg-RX-API-DMAC10.html)
IL (1) IL175503A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA06005219A (cg-RX-API-DMAC10.html)
WO (1) WO2005047478A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200603780B (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2545359C (en) * 2003-11-12 2012-11-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for regulation of tumor necrosis factor-alpha
IL169622A0 (en) * 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법
US20090263377A1 (en) * 2008-04-10 2009-10-22 Charles Lin Il-32b-targeted diagnosis and therapy
JP5395725B2 (ja) * 2010-04-05 2014-01-22 富士フイルム株式会社 電子内視鏡システム
WO2012142597A1 (en) * 2011-04-15 2012-10-18 The Regents Of The University Of California A method for generating potent dendritic cells
US9273284B2 (en) 2011-04-19 2016-03-01 The Regents Of The University Of California Method for generating potent dendritic cells
CN102392043A (zh) * 2011-12-13 2012-03-28 江南大学 毕赤酵母制备人白细胞介素32β的方法
CN102660552B (zh) * 2011-12-30 2014-03-19 西北农林科技大学 一种牛白细胞介素32γ亚型的分子克隆/稳转细胞系的建立及其方法
CN110724193B (zh) 2013-07-03 2023-05-05 因美诺克股份公司 人单克隆抗il-32抗体、多核苷酸、载体、宿主细胞、制备方法、组合物及应用
CN104975041B (zh) * 2014-12-19 2018-01-23 中山大学 一种促进单核细胞向巨噬细胞分化的方法
KR101693275B1 (ko) 2015-03-03 2017-01-05 충북대학교 산학협력단 IFN-γ 및 IL-32γ를 유효성분으로 포함하는 항암용 조성물
GB201701404D0 (en) * 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
US20200264192A1 (en) * 2017-09-28 2020-08-20 Turun Yliopisto Interleukin 32 as a biomarker of type 1 diabetes
WO2025137261A1 (en) * 2023-12-20 2025-06-26 Verily Life Sciences Llc Methods of diagnosing and treating rheumatoid arthritis by identifying inflammatory initiators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
GB9214857D0 (en) * 1992-07-13 1992-08-26 Medical Res Council Human nucleic acid fragments and their use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US6706491B1 (en) 1999-04-09 2004-03-16 The Board Of Trustees Of The University Of Illinois Reagents and methods for identifying and modulating expression of genes regulated by p21
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP1661986A1 (en) * 2000-11-17 2006-05-31 Nuvelo, Inc. Nucleic acids and polypeptides enocoded thereby that are member of the kallikrein gene familyNovel nucleic acids and polypeptides
WO2002048310A2 (en) 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
JP2004536581A (ja) 2001-04-18 2004-12-09 ジェンセット ソシエテ アノニム 分泌される可能性のあるタンパク質をコードする全長ヒトｃＤＮＡ
WO2002094864A2 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
WO2002096943A1 (en) 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
US7125663B2 (en) 2001-06-13 2006-10-24 Millenium Pharmaceuticals, Inc. Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer
US20030073623A1 (en) * 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
US20050130145A1 (en) 2001-10-03 2005-06-16 Henry Yue Secreted proteins
WO2003080640A1 (en) 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Lymphatic and blood endothelial cell genes
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US20050048490A1 (en) 2002-09-26 2005-03-03 Incyte Corp. Proteins associated with cell growth, differentiation, and death
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2545359C (en) * 2003-11-12 2012-11-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for regulation of tumor necrosis factor-alpha
KR100565698B1 (ko) 2004-12-29 2006-03-28 디지탈 지노믹스(주) 급성골수성백혈병(aml), b-세포형 급성임파구성백혈병(b-all), t 세포형 급성임파구성백혈병(t-all) 진단용 마커
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 ｉｌ-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 ｉｌ-32측정법

Also Published As

Publication number Publication date
CN101018808B (zh) 2014-07-23
US20120183601A1 (en) 2012-07-19
US8138312B2 (en) 2012-03-20
CN101018808A (zh) 2007-08-15
JP2007513609A (ja) 2007-05-31
BRPI0416467A (pt) 2007-03-06
AU2004290049A1 (en) 2005-05-26
EP2357238A2 (en) 2011-08-17
EA200600936A1 (ru) 2006-10-27
EP2357238A3 (en) 2012-02-01
EP1692175A2 (en) 2006-08-23
US8735358B2 (en) 2014-05-27
MXPA06005219A (es) 2007-01-19
US20110190476A1 (en) 2011-08-04
US20070071719A1 (en) 2007-03-29
WO2005047478A3 (en) 2006-06-01
US20140235829A1 (en) 2014-08-21
WO2005047478A2 (en) 2005-05-26
JP2012050446A (ja) 2012-03-15
US7560265B2 (en) 2009-07-14
ZA200603780B (en) 2007-06-27
AU2004290049B2 (en) 2011-09-29
JP4979385B2 (ja) 2012-07-18
IL175503A0 (en) 2006-09-05
EP1692175A4 (en) 2008-09-17
EA012567B1 (ru) 2009-10-30
CA2545359A1 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
US8735358B2 (en) Methods for treating cancer by regulation of tumor necrosis factor-alpha
US20100297065A1 (en) Homogeneous preparations of il-31
KR20110048536A (ko) 자가면역 질병에서 ｉｌ－２２, ｉｌ－１７ 및 ｉｌ－１ 패밀리 시토킨의 용도
TW200539891A (en) Methods of modulating cytokine activity; related reagents
WO1994009137A1 (en) Antibodies against type 2 tumor necrosis factor receptor
US7135303B2 (en) Regulators of type-1 tumor necrosis factor receptor and other cytokine receptor shedding
MXPA02008079A (es) Uso de inhibidores de il-18.
US7696154B2 (en) Methods for treating interleukin-18 mediated disorders with interleukin-18 binding proteins
PT1812476E (pt) Anticorpos anti-il-22ra e parceiros de ligação e métodos de utilização no tratamento de inflamações
SK15562002A3 (sk) Použitie IL-18 inhibítora, použitie expresného vektora obsahujúceho sekvenciu kódujúcu IL-18 inhibítor, použitie vektora na indukciu a/alebo zosilnenie endogénnej produkcie IL-18 inhibítora v bunke a použitie bunky s produkciou IL-18 inhibítora
AU756759B2 (en) Protein that binds trail
Dinarello et al. Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure
Maiti et al. A monoclonal antibody specific for rat IL-18BP and its application in determining serum IL-18BP
AU2023800A (en) Novel dnas and polypeptides
US20090148440A1 (en) Antibodies against interleukin-22 binding protein and its uses for the treatment of metabolic disorders
JP2024508048A (ja) Ｓｉｇｌｅｃ－１５結合タンパク質の調製およびその使用
WO1996026954A1 (en) FsF-1 AND THE EARLY DETECTION OF FIBROSIS
HK40057229A (en) Anti-il-17a antibody and use thereof
JP2000236884A (ja) ペプチド
HK1173453A (en) Anti-il-22ra antibodies and binding partners and methods of using in inflammation
HK1158224A (en) Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
HK1111195A (en) NEUTROKINE α

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151112